Herantis Pharma PLC · OMXHEX:HRTIS
Herantis Pharma — Investor Presentation (May 2021)
23 slides from Herantis Pharma's investor presentation, May 2021
Slide 1: Company presentation
HERANTIS PHARMA Company presentation
Slide 2: Disclaimer
Disclaimer By accepting to receive this presentation from Herantis Pharma Plc (the "Company"), you agree to be bound by the following conditions. This presentation and any oral communication in connection with it (the "Information") are strictly confidential and are being provided to you solely for
Slide 3: Company Overview
Company Overview • Headquartered in Helsinki, listed on Nasdaq First North Finland (2014) and Sweden (2019) • Pure play CNS biotech company as of 2021 • Research focus is on assets that modify disease pathology • Disease focus is on Parkinson’s and other neurodegenerative diseases • Looking to bring
Slide 4: A Pure Play CNS Company Focused on Neurodegenerative Diseases
A Pure Play CNS Company Focused on Neurodegenerative Diseases Drug Research/ Next Anticipated Indication Discovery Phase 1 Phase 2 Phase 3 Market Potential Candidate/Project Preclinical Milestone #1. Parkinson's Disease Met Primary Endpoints at 12-Month Approx. (Intracranial surgery CED Expanding to
Slide 5: CDNF & xCDNF Key Data
CDNF & xCDNF Key Data 1. Mechanism of Action 2. Safety 3. Biomarkers 4. Genetics 5. Potency 5
Slide 6: 1. Proteostasis
1. Proteostasis 6 6
Slide 7: CDNF and xCDNF Act Powerfully On Key System Of The Body - Proteostasis
CDNF and xCDNF Act Powerfully On Key System Of The Body - Proteostasis • Proteostasis regulates proteins within the body and influences the fate of every protein from synthesis to degradation • Particularly important in nondividing, long-lived cells, such as neurons, as its failure is implicated wit
Slide 8: CDNF Targets Core Pathology Of Parkinsons Disease
CDNF Targets Core Pathology Of Parkinsons Disease Proteins are the building blocks of everything in the body. Functionality of all cells (particularly neurons) depends on the balance of the three cornerstones of proteome regulation: synthesis, folding and degradation. If any of these becomes dysfunc
Slide 9: 2. Safety
2. Safety 9 9
Slide 10: Phase I Safety Study Successfully Completed
Phase I Safety Study Successfully Completed Main Study – 6 months Extension Study – 6 months Follow-up Study – 4 years Mid-dose CDNF Treatment groups Vehicle (n=6) High-dose CDNF Safety follow-up All patients Mid-dose CDNF (n=6) High-dose CDNF (n=5) Monthly Infusions x 6 Monthly Infusions x 6 Safety
Slide 11: CDNF Safety Established
CDNF Safety Established • Majority of the reported drug-related adverse events AE’s were mild and transient • Similar safety profile in Main (0 – 6 Months) and Extension (6 – 12 Months) study • Similar safety profile between dose-groups • No dose-limiting toxicities related to CDNF • Serious SAE’s r
Slide 12: 3. Biomarkers & Genetics
3. Biomarkers & Genetics 1 2 12
Slide 13: Emerging Evidence Of CDNF Treatment Effects On Biomarkers
Emerging Evidence Of CDNF Treatment Effects On Biomarkers • Biomarkers in Cerebrospinal Fluid (CSF) change in response to CDNF treatment in some patients • Correlated with improvements in motor function and biological dopamine signals • Some subjects found to carry mutation etiopathologically relate
Slide 14: Emerging Evidence Linking Genetic + Clinical + Imaging + Biomarker Data
Emerging Evidence Linking Genetic + Clinical + Imaging + Biomarker Data 4 ○ 60+ year ○ Disease duration: 10 years (from first motor symptoms) ○ 6 months placebo, followed 2 3 by 6 months CDNF Motor Score Imaging PLACEBO CDNF 1 Improvement Improvement Genotype LRRK2 (G2019S) -12 pts from baseline Sig
Slide 15: 4. xCDNF
4. xCDNF 1 5 15
Slide 16: xCDNF - Engineered To Achieve Essential Therapeutic Parameters
xCDNF - Engineered To Achieve Essential Therapeutic Parameters • Synthetic peptidomimetic compound using only smallest most potent fragments of parent CDNF • Engineered to maintain potency in protecting neurons, as well as to cross the blood brain N-terminal domain barrier (BBB) - both critical elem
Slide 17: BBB Penetration: At Therapeutic Levels + Extended Half Life In Vivo
BBB Penetration: At Therapeutic Levels + Extended Half Life In Vivo DUAL (BRAIN AND PLASMA) MICRODIALYSIS STUDY IN MICE Kp,uu,brain = 0.216 ✅ 17
Slide 18: Potency: Protects Dopamine Neurons + Reduces α-Synuclein Aggregates In Vivo
Potency: Protects Dopamine Neurons + Reduces 𝜶𝜶-Synuclein Aggregates In Vivo High protection of dopamine neurons, plus almost complete eradication of 𝛂𝛂-synuclein aggregates Improvement Improvement +11% +46% ✅ STUDY: Test compound CP-C-096 was administrated subcutaneously in dose 1mg/kg or 10…
Slide 19: Attenuates Unfolded Protein Response And ER Stress, Reduces Cell Death
Attenuates Unfolded Protein Response And ER Stress, Reduces Cell Death Microglial Activation and Unfolded Protein Response Are Attenuated in the Substantia Nigra of Mice Treated with CP-C-096 >80% reduction of key neuroinflammatory/microgliosis marker, and 85% and 52% reductions of activated IRE1 an
Slide 20: Summary
Summary 2 0 20
Slide 21: Timelines, Newsflow, Next Steps
Timelines, Newsflow, Next Steps Commercialization Approval Phase III (Safety & Efficacy) Phase II ( Safety & Efficacy) Phase I (Safety & Dosage) H2 2021: Complete formulation and CDNF Intracranial pre-clinical new admin IND Enabling (Toxicology & CMC) routes for CDNF in CDNF Preclinical/ Proof-of-Co
Slide 22: Summary CDNF and xCDNF: Persuasive Picture Emerging Across MoA, Clinical, Biomarker, Imaging And Genetic Data
Summary CDNF and xCDNF: Persuasive Picture Emerging Across MoA, Clinical, Biomarker, Imaging And Genetic Data 1. Strong multimodal MoA for CDNF and xCDNF: • Restores proteostasis and reduces neuroinflammation – both key elements of Parkinsons • Evidence of target engagement 2. CDNF • Established saf
Slide 23: Thank You!
Thank You! 2 3 23